Propella Therapeutics Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-02-23 16:22:522021-04-26 14:36:32Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer
Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium on February 11, 2021.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-02-22 11:33:212021-02-22 16:32:08Presentation: Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model (citation and abstract are found at https://meetinglibrary.asco.org/record/194919/abstract)
Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-02-20 00:37:592021-02-20 00:38:00Presentation: Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
Propella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-15 01:30:302021-01-15 01:43:37Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:57:112021-01-14 18:24:28Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:54:092021-01-14 18:25:20Treatment of Arthritis with Topical Capsaicin: A Double-Blind Trial
Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer
/in all, press releases /by georgePropella Therapeutics Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Presentation: Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model (citation and abstract are found at https://meetinglibrary.asco.org/record/194919/abstract)
/in all, presentations /by georgePropella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium on February 11, 2021.
Presentation: Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
/in all, presentations /by georgePropella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)
/in all, presentations /by georgePropella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.
Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
/in all, references (CGS-200-5) /by georgeTreatment of Arthritis with Topical Capsaicin: A Double-Blind Trial
/in all, references (CGS-200-5) /by george